Navigation Links
Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
Date:1/13/2010

BEIJING, Jan. 13 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA), a leading provider of biopharmaceutical products in China, announced today that it has received its fifth purchase order for its H1N1 vaccine, PANFLU.1(TM), from China's Ministry of Industry and Information Technology for the national purchase plan. Under this purchase order, Sinovac is required to deliver an additional 8.57 million doses of PANFLU.1(TM) (15ug/0.5ml) to the Chinese Central Government, of which 2.33 million doses are expected to be delivered before March 15, 2010, and the balance of 6.23 million doses to be stockpiled by the government in Sinovac's warehouse facility.

In aggregate, Sinovac has received orders of PANFLU.1 from the Chinese government for a total 20.05 million doses, and 10.23 million doses of PANFLU.1 have been delivered to date for the Chinese vaccination campaign. In 2009, the Company completed the expansion of its production line used to manufacture the seasonal influenza, H1N1 and H5N1 vaccines, thereby increasing its annual production capacity by approximately 60%.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "This fifth order from the Chinese Central Government demonstrates Sinovac's continuing ability to complete its national H1N1 vaccine stockpiling tasks in a timely manner. The production capacity expansion has continued to serve its purpose in positioning Sinovac to operate even more efficiently towards our goal of providing citizens of China with affordable, international-quality vaccines."

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
2. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
3. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
4. Sinovac Files Shelf Registration Statement
5. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
6. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
7. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
8. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
9. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
10. Jiangbo Pharmaceuticals Obtains Renewal of GMP Certificate
11. Derma Sciences Obtains Exclusive Worldwide Rights to MEDIHONEY(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Inc. (NYSE AMEX: ULU), a specialty pharmaceutical ... management and oral care products, today announced it has completed ... Company,s Chairman, President, and Chief Executive Officer. The Company intends ... The convertible notes will bear interest at the rate of ...
... Information Systems ("SIS"), a leader in perioperative information ... has extended its enterprise agreement with SIS by ... implementation will start at North Shore University Hospital and ... hospitals. (Logo:   http://photos.prnewswire.com/prnh/20080722/SISLOGO ) ...
Cached Medicine Technology:ULURU Inc. Raises $140,000 in Convertible Debt Offering 2North Shore-LIJ Health System Selects SIS Anesthesia 2North Shore-LIJ Health System Selects SIS Anesthesia 3North Shore-LIJ Health System Selects SIS Anesthesia 4
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... inflammation in non-cancerous prostate tissue may have nearly twice ... with no inflammation, according to results of a new ... Cancer Center. , The link between persistent inflammation and ... prostate cancer those with a Gleason score between ... most aggressive and rapidly growing prostate cancers. , "What ...
(Date:4/17/2014)... targets that could be used to provide relief ... London made the discovery when researching how pain ... body. , Dr Marzia Malcangio said: "We have ... and our findings could help chemotherapy patients who ... side effect of some chemotherapy drugs (such as ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced ... Food and Drug Administration to manufacture and market,Ciclopirox ... The product has been determined to be ... Nail Lacquer, indicated for the,treatment of mild to ...
... Study Data Demonstrated Improved Progression-free Survival with Campath, ... ,Genzyme Corp. (Nasdaq: GENZ ) and Bayer ... that the U.S. Food and Drug Administration,(FDA) has ... (alemtuzumab) and granted regular approval for single-agent,Campath for ...
... Pa., Sept. 21 Cephalon, Inc. (Nasdaq:,CEPH) today ... Application (NDA) to,the U.S. Food and Drug Administration ... treatment of patients with chronic,lymphocytic leukemia (CLL). CLL ... with an estimated 15,000 new cases diagnosed every ...
... grains for breakfast, such as whole-grain barley or rye, ... breakfast, lunch, and dinner. It was previously not known ... This is due to a combination of low GI ... occur in certain grain products. The findings are presented ...
... study by researchers at the University of Southern California suggests ... Researchers found that a storyline on the primetime NBC network ... eating habits had a positive impact on the attitudes and ... in the Sept. 14 Journal of Health Communication and now ...
... Insights might produce treatments to kill off cancer cells, ... New information about a process called unplanned cell death, ... disease, cancer, stroke and other life-threatening conditions, scientists say. ... natural, healthy programmed cell death. Necrosis is an unplanned ...
Cached Medicine News:Health News:Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 2Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 3Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 4Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 5Health News:FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia 6Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 2Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 3Health News:Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia 4Health News:Right breakfast bread keeps blood sugar in check all day 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Clues to Cell Death Could Fight Disease 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: